MacLeod M J, McLay J
Department of Medicine and Therapeutics, University of Aberdeen, Scotland.
Drugs. 1998 Aug;56(2):189-202. doi: 10.2165/00003495-199856020-00003.
Hypertension and diabetes mellitus are both common conditions associated with a high morbidity and mortality. When the two conditions occur together, as they do in 50% of diabetic individuals, the result is a 7.2-fold increase in mortality. If hypertension occurs in association with diabetes mellitus and diabetic nephropathy, mortality rises to 37-fold above that of a healthy population. Despite the increase in incidence of nephropathy, cardiovascular disease remains the major cause of death in diabetic individuals. Therapy should therefore take into consideration the results of large, placebo-controlled trials which have shown reduction in cardiovascular morbidity and mortality as a result of active treatment. Although studies with the newer antihypertensive agents such as calcium antagonists and angiotensin converting enzyme (ACE) inhibitors are ongoing, only diuretics and beta-adrenoceptor antagonists have been clearly shown to reduce cardiovascular risk. Despite concerns regarding adverse metabolic effects and loss of hypoglycaemic awareness, beta-blockers and diuretics do have a role in the management of diabetic patients. While it is clear that ACE inhibitors reduce the progression of diabetic nephropathy, evidence suggests that diuretics may be just as effective. However, unlike diuretics or beta-blockers, ACE inhibitors have no proven benefit in the prevention of stroke of myocardial infarction. Despite the claims of metabolic neutrality made for many antihypertensive agents there appears to be no advantage in their use in the majority of hypertensive diabetic patients, except where there exist specific contraindications to established therapies.
高血压和糖尿病都是常见病症,发病率和死亡率都很高。当这两种病症同时出现时(50%的糖尿病患者会出现这种情况),死亡率会增加7.2倍。如果高血压与糖尿病及糖尿病肾病同时出现,死亡率会升至健康人群的37倍。尽管肾病发病率有所上升,但心血管疾病仍是糖尿病患者的主要死因。因此,治疗应考虑大型安慰剂对照试验的结果,这些试验表明积极治疗可降低心血管发病率和死亡率。虽然针对新型抗高血压药物(如钙拮抗剂和血管紧张素转换酶(ACE)抑制剂)的研究仍在进行,但只有利尿剂和β-肾上腺素能受体拮抗剂已被明确证明可降低心血管风险。尽管人们担心β受体阻滞剂和利尿剂会产生不良代谢影响并导致低血糖意识丧失,但它们在糖尿病患者的治疗中仍有作用。虽然ACE抑制剂可减缓糖尿病肾病的进展这一点很明确,但有证据表明利尿剂可能同样有效。然而,与利尿剂或β受体阻滞剂不同,ACE抑制剂在预防中风或心肌梗死方面尚无已证实的益处。尽管许多抗高血压药物声称具有代谢中性,但在大多数高血压糖尿病患者中使用这些药物似乎并无优势,除非对既定疗法存在特定禁忌证。